Ex vivo and in vivo evaluation of overexpressed VLA-4 in multiple myeloma using LLP2A imaging agents

Journal of Nuclear Medicine

Volumn 57, Issue 4, 2016, Pages 640-645

  Soodgupta, Deepti ^a   Zhou, Haiying ^b   Beaino, Wissam ^c   Lu, Lan ^a   Rettig, Michael ^a   Snee, Mark ^a   Skeath, James ^a   DiPersio, John F ^a   Akers, Walter J ^b   Laforest, Richard ^b   Anderson, Carolyn J ^c   Tomasson, Michael H ^a   Shokeen, Monica ^b  

^a WASHINGTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b WASHINGTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c UNIVERSITY OF PITTSBURGH SCHOOL OF MEDICINE   (United States)

Author keywords

Animal imaging; Dosimetry; LLP2A; Molecular imaging; Multiple myeloma; Radiobiology dosimetry; VLA 4 specificity

Indexed keywords

BIOLOGICAL MARKER; COPPER LLP2A C 64; FLUORODEOXYGLUCOSE F 18; LLP2A SULFO CYANINE5; RADIOPHARMACEUTICAL AGENT; UNCLASSIFIED DRUG; VERY LATE ACTIVATION ANTIGEN 4; CARBANILAMIDE DERIVATIVE; COPPER; DIPEPTIDE; LLP2A COMPOUND; TUMOR MARKER;

ADULT; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CELL SELECTION; COMPUTER ASSISTED EMISSION TOMOGRAPHY; CONTROLLED STUDY; DOSIMETRY; DRUG CLEARANCE; DRUG DETERMINATION; DRUG HALF LIFE; DRUG PROTEIN BINDING; DRUG SPECIFICITY; DRUG TUMOR LEVEL; DRUG URINE LEVEL; EFFECTIVE DOSE (PHARMACOLOGY); EX VIVO STUDY; FLOW CYTOMETRY; HUMAN; HUMAN TISSUE; IN VIVO STUDY; ISOTOPE LABELING; KNOCKOUT MOUSE; MALE; MOLECULAR IMAGING; MONOCYTE; MOUSE; MULTIPLE MYELOMA; NONHUMAN; PRIORITY JOURNAL; PROTEIN ANALYSIS; PROTEIN ELECTROPHORESIS; PROTEIN EXPRESSION; RADIOACTIVITY; T LYMPHOCYTE; UPREGULATION; WILD TYPE; ANIMAL; BAGG ALBINO MOUSE; C57BL MOUSE; DIAGNOSTIC IMAGING; METABOLISM; POSITRON EMISSION TOMOGRAPHY; PROTEIN CONFORMATION; SYNTHESIS; TISSUE DISTRIBUTION; TUMOR CELL LINE; WHOLE BODY IMAGING;

ANIMALS; BIOMARKERS, TUMOR; CELL LINE, TUMOR; COPPER RADIOISOTOPES; DIPEPTIDES; HUMANS; INTEGRIN ALPHA4BETA1; MICE, INBRED BALB C; MICE, INBRED C57BL; MICE, KNOCKOUT; MULTIPLE MYELOMA; PHENYLUREA COMPOUNDS; POSITRON-EMISSION TOMOGRAPHY; PROTEIN CONFORMATION; RADIOPHARMACEUTICALS; TISSUE DISTRIBUTION; WHOLE BODY IMAGING;

EID: 84963935716     PISSN: 01615505     EISSN: 2159662X     Source Type: Journal    
DOI: 10.2967/jnumed.115.164624     Document Type: Article

References (30)

1. Anderson KC, Alsina M, Bensinger W, et al. Multiple myeloma, version 1.2013. J Natl Compr Canc Netw. 2013;11:11-17.
2. Kuehl WM, Bergsagel PL. Molecular pathogenesis of multiple myeloma and its premalignant precursor. J Clin Invest. 2012;122:3456-3463.
3. Rajkumar SV, Dimopoulos MA, Palumbo A, et al. International myeloma working group updated criteria for the diagnosis of multiple myeloma. Lancet Oncol. 2014;15:e538-e548.
4. Wang TF, Ahluwalia R, Fiala MA, et al. The characteristics and outcomes of patients with multiple myeloma dual refractory or intolerant to bortezomib and lenalidomide in the era of carfilzomib and pomalidomide. Leuk Lymphoma. 2014;55:337-341.
5. 18F-fluoro-deoxyglucose positron emission tomography in assessment of myeloma-related bone disease: a systematic review. Cancer. 2012;118:1971-1981.
6. Schlesinger M, Bendas G. Contribution of very late antigen-4 (VLA-4) integrin to cancer progression and metastasis. Cancer Metastasis Rev. 2015;34:575-591.
7. Sanz-Rodríguez F, Teixido J. VLA-4-dependent myeloma cell adhesion. Leuk Lymphoma. 2001;41:239-245.
8. Sanz-Rodríguez F, Hidalgo A, Teixido J. Chemokine stromal cell-derived factor-1alpha modulates VLA-4 integrin-mediated multiple myeloma cell adhesion to CS-1/fibronectin and VCAM-1. Blood. 2001;97:346-351.
9. Nishinarita S, Shimada H, Ito T, et al. Expression of beta 1 integrins (very late antigens-4 and-5) on myeloma cells and clinical correlates in patients with multiple myeloma. J Int Med Res. 1998;26:37-42.
10. Peng L, Liu R, Andrei M, Xiao W, Lam KS. In vivo optical imaging of human lymphoma xenograft using a library-derived peptidomimetic against alpha4beta1 integrin. Mol Cancer Ther. 2008;7:432-437.
11. Peng L, Liu R, Marik J, Wang X, Takada Y, Lam KS. Combinatorial chemistry identifies high-affinity peptidomimetics against alpha4beta1 integrin for in vivo tumor imaging. Nat Chem Biol. 2006;2:381-389.
12. Soodgupta D, Hurchla MA, Jiang M, et al. Very late antigen-4 (a4b1 integrin) targeted PET imaging of multiple myeloma. PLoS One. 2013;8:e55841.
13. 68Ga-and 64Cu-labeled NODAGA and CB-TE1A1P-LLP2A conjugates. J Nucl Med. 2014;55:1856-1863.
14. Soodgupta D, Pan D, Cui G, et al. Small molecule MYC inhibitor conjugated to integrin-targeted nanoparticles extends survival in a mouse model of disseminated multiple myeloma. Mol Cancer Ther. 2015;14:1286-1294.
15. Rettig MP, Ansstas G, DiPersio JF. Mobilization of hematopoietic stem and progenitor cells using inhibitors of CXCR4 and VLA-4. Leukemia. 2012;26:34-53.
16. Priestley GV, Ulyanova T, Papayannopoulou T. Sustained alterations in biodistribution of stem/progenitor cells in Tie2Cre1 alpha4(f/f) mice are hematopoietic cell autonomous. Blood. 2007;109:109-111.
17. Masumoto A, Hemler ME. Multiple activation states of VLA-4. Mechanistic differences between adhesion to CS1/fibronectin and to vascular cell adhesion molecule-1. J Biol Chem. 1993;268:228-234.
18. Dormond O, Ponsonnet L, Hasmim M, Foletti A, Ruegg C. Manganese-induced integrin affinity maturation promotes recruitment of alpha V beta 3 integrin to focal adhesions in endothelial cells: evidence for a role of phosphatidylinositol 3-kinase and Src. Thromb Haemost. 2004;92:151-161.
19. Laforest R, Dehdashti F, Lewis JS, Schwarz SW. Dosimetry of 60/61/62/64Cu-ATSM: a hypoxia imaging agent for PET. Eur J Nucl Med Mol Imaging. 2005;32:764-770.
20. Mulligan M, Chirindel A, Karchevsky M. Characterizing and predicting pathologic spine fractures in myeloma patients with FDG PET/CT and MR imaging. Cancer Invest. 2011;29:370-376.
21. Burger JA, Ghia P, Rosenwald A, Caligaris-Cappio F. The microenvironment in mature B-cell malignancies: a target for new treatment strategies. Blood. 2009;114:3367-3375.
22. 11CD11b1myeloid-derived suppressor cells. PLoS One. 2012;7:e48871.
23. Fowler JA, Mundy GR, Lwin ST, Edwards CM. Bone marrow stromal cells create a permissive microenvironment for myeloma development: a new stromal role for Wnt inhibitor Dkk1. Cancer Res. 2012;72:2183-2189.
24. Teoh G, Urashima M, Greenfield EA, et al. The 86-kD subunit of Ku autoantigen mediates homotypic and heterotypic adhesion of multiple myeloma cells. J Clin Invest. 1998;101:1379-1388.
25. Uchiyama H, Barut BA, Chauhan D, Cannistra SA, Anderson KC. Characterization of adhesion molecules on human myeloma cell lines. Blood. 1992;80:2306-2314.
26. Hallek M, Bergsagel PL, Anderson KC. Multiple myeloma: increasing evidence for a multistep transformation process. Blood. 1998;91:3-21.
27. Uchiyama H, Barut BA, Mohrbacher AF, Chauhan D, Anderson KC. Adhesion of human myeloma-derived cell lines to bone marrow stromal cells stimulates interleukin-6 secretion. Blood. 1993;82:3712-3720.
28. Masellis-Smith A, Belch AR, Mant MJ, Pilarski LM. Adhesion of multiple myeloma peripheral blood B cells to bone marrow fibroblasts: a requirement for CD44 and alpha4beta7. Cancer Res. 1997;57:930-936.
29. Urashima M, Chen BP, Chen S, et al. The development of a model for the homing of multiple myeloma cells to human bone marrow. Blood. 1997;90:754-765.
30. Vanderkerken K, De Raeve H, Goes E, et al. Organ involvement and phenotypic adhesion profile of 5T2 and 5T33 myeloma cells in the C57BL/KaLwRij mouse. Br J Cancer. 1997;76:451-460.